Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Blood

Volumn 126, Issue 26, 2015, Pages 2798-2804

  Forero Torres, Andres ^a   Holkova, Beata ^b   Goldschmidt, Jerome ^c   Chen, Robert ^d   Olsen, Gregg ^e   Boccia, Ralph V ^f   Bordoni, Rodolfo E ^g   Friedberg, Jonathan W ^h   Sharman, Jeff P ⁱ   Palanca Wessels, Maria Corinna ^j   Wang, Yinghui ^j   Yasenchak, Christopher A ⁱ  

^a University of Alabama at Birmingham   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c Oncology Hematology Associates of Southwest Virginia   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Providence Saint Joseph Medical Center   (United States)

^f Center for Cancer and Blood Disorders   (United States)

^g Georgia Cancer Specialists   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ Willamette Valley Cancer Institute and Research Center   (United States)

^j SEATTLE GENETICS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CARBOPLATIN; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; INCIDENCE; MACULOPAPULAR RASH; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RISK FACTOR; SENSORY NEUROPATHY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED;

EID: 84954484157     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-06-644336     Document Type: Article

References (36)

1. Medeiros LJ, Greiner TC. Hodgkin's disease. Cancer. 1995;75(suppl 1):357-369.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
3. Kennedy BJ, Loeb V Jr, Peterson VM, Donegan WL, Natarajan N, Mettlin C. National survey of patterns of care for Hodgkin's disease. Cancer. 1985;56(11):2547-2556.
4. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR; Northern Region Lymphoma Group. Hodgkin's disease in the elderly: a populationbased study. Br J Haematol. 2002;119(2): 432-440.
5. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-6015.
6. Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71(3):222-232.
7. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119(3): 692-695.
8. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76-86.
9. Evens AM, Sweetenham JW, Horning SJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park). 2008;22(12):1369-1379.
10. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 suppl 2):18-24.
11. Lichtman SM, Wildiers H, Chatelut E, et al; International Society of Geriatric Oncology Chemotherapy Taskforce. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol. 2007;25(14):1832-1843.
12. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vc MMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-1465.
13. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540-10547.
14. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
15. Gopal AK, Chen R, Smith SE, et al. Three-year follow-up data and characterization of long-term remissions from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood. 2013;122(21):4382.
16. Gopal AK, Bartlett NL, Forero-Torres A, et al. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10): 2328-2334.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41.
18. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5): 579-586.
19. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53(8):866-877.
20. Kawas C, Karagiozis H, Resau L, Corrada M, Brookmeyer R. Reliability of the Blessed Telephone Information-Memory-Concentration Test. J Geriatr Psychiatry Neurol. 1995;8(4): 238-242.
21. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9): 1998-2005.
22. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457-3465.
23. Collett D. Statistical inference for binary data. Modelling Binary Data. 1st ed. London, United Kingdom: Chapman and Hall; 1991:17-42.
24. Stewart AL, Kamberg CJ. Physical functioning measures. In: Stewart AL, Ware JE Jr, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:86-101.
25. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36(4):428-434.
26. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142-148.
27. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6): 705-714.
28. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. Available at: http://seer.cancer.gov/csr/1975-2011/. Accessed August 10, 2015.
29. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
30. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
31. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17): 2036-2038.
32. Hurria A, Dale W, Mooney M, et al; Cancer and Aging Research Group. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587-2594.
33. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179-184.
34. LaCasce A, Bociek RG, Matous J, et al. Brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma who are relapsed or refractory after frontline therapy [abstract]. Blood. 2014;124(21). Abstract 293.
35. Yang J, Palanca-Wessels MC, Wang Y, Josephson N, Peng SL. Pharmacokinetics of brentuximab vedotin in Hodgkin lymphoma patients aged 60 and above [abstract]. Clin Pharmacol Ther. 2015;97(Supplement S1). Abstract S85.
36. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290-1296.